<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Each nineteen patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) have been treated by allogeneic bone marrow transplantation (BMT) at Hyogo College of Medicine between 1980 and 1991 </plain></SENT>
<SENT sid="1" pm="."><plain>Rejection was one of the major problems for SAA patients </plain></SENT>
<SENT sid="2" pm="."><plain>Conditioning regimen including irradiation reduced the rejection rate, but <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancers</z:e> may develop as the dose of irradiation increased </plain></SENT>
<SENT sid="3" pm="."><plain>It is practically important to determine the indication of BMT for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) </plain></SENT>
<SENT sid="4" pm="."><plain>We considered the indication of BMT for those who have abnormal karyotypes and/or life threatening complications </plain></SENT>
<SENT sid="5" pm="."><plain>Five out of nine patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA are surviving after BMT </plain></SENT>
<SENT sid="6" pm="."><plain>Four out of ten cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> and overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> are alive </plain></SENT>
<SENT sid="7" pm="."><plain>BMT should be recommended for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who satisfy the above conditions, if suitable donors are available </plain></SENT>
<SENT sid="8" pm="."><plain>However, it remains to be determined whether the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> should be treated with chemotherapy prior to the preconditioning for BMT </plain></SENT>
</text></document>